Press Releases AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:00 18/07/2025 BST			5-day change	1st Jan Change
10,294.00 ^GBX	-0.17%		-1.49%	-1.66%

07-18	Foreign firms' executives entangled in Chinese probes	RE
07-18	Foreign firms' executives entangled in Chinese probes	RE

Press Releases

AstraZeneca : Update on anselamimab in AL amyloidosis	07-16	PU
AstraZeneca PLC - Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension	07-14	AQ
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension	07-14	BU
AstraZeneca : Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension	07-14	PU
Baxdrostat met primary endpt in BaxHTN PhIII trial	07-14	AQ
AstraZeneca - Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer	07-07	AQ
AstraZeneca : Imfinzi approved in the EU for bladder cancer	07-04	PU
Modella AI Announces Agreement to Accelerate AI-Driven Oncology Clinical Development	07-03	AQ
Astrazeneca CEO mulls move to shift LSE listing	07-02	AQ
DATROWAY(R) Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer	06-24	AQ
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer	06-24	BU
Datroway approved in US for EGFRm lung cancer	06-24	AQ
AstraZeneca : Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer	06-23	PU
AstraZeneca : Alexion data presented at EAN 2025 highlights its leadership and commitment to improving patient outcomes in rare neurological diseases	06-21	PU
Pharmacy Alert: AstraZeneca Sends "Unreserved Cooperation" Letters Demanding Farxiga® Dispensing Records	06-19	AQ
AstraZeneca : enters into collaboration with CSPC	06-13	PU
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU(R) Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer	06-10	AQ
New tRNA tech aims to rewrite rare disease treatment	06-09	AQ
AstraZeneca : Fixed-duration Calquence approved in EU for 1L CLL	06-06	PU
Lumito establishes Scientific Advisory Board with leading international experts in drug development, pathology, and oncology	06-05	AQ
AstraZeneca : Biographies (ASCO2025 biographies 20250602)	06-03	PU
AstraZeneca : Presentation (ASCO2025 Presentation 20250602b)	06-03	PU
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial	06-02	BU
AstraZeneca - Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial	06-02	AQ
AstraZeneca - Imfinzi regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial	06-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

AstraZeneca's CEO reportedly considers listing in the United States

July 02, 2025 at 08:39 am

ASTRAZENECA : Sustained operational strength leads to an upgrade

May 20, 2025 at 03:42 pm

AstraZeneca Gets Profit Boost From Diabetes, Cancer Drugs

April 29, 2025 at 10:46 am